Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO ... as well as to continue our trials. We’re expanding the label not just across regions ...

New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), ...

CRISPR and Vertex have obtained approval for clinical trial applications for several ... Novartis yesterday unveiled data showing its crizanlizumab reduced occurrence of the painful and ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

Intellia has reported results from a phase 2 trial of its gene ... who said the data "underscore[s] the tremendous potential of [the] in vivo CRISPR gene editing therapy" and "sets NTLA-2002 ...

But that's not so. Indirect costs include lab space, data storage, regulatory compliance and administrative support. The ...